| Renin-angiotensin-aldosterone system inhibitors in patients after NSTE-ACS - Summary of recommendations and evidence | ||
|---|---|---|
| Renin-angiotensin-aldosterone system inhibitors in patients after NSTE-ACS - Summary of recommendations and evidence | I | A |
| Spironolactone is recommended in patients with LVEF ≤ 40% associated with HF or DM. | I | A |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.